[April 05, 2012]

Research and Markets: Germany Pharmaceuticals and Healthcare Report Q2 2012 - In 2011, Germany's Drug Market Was the Fourth Largest Globally After the US, Japan and China

Research and Markets (http://www.researchandmarkets.com/research/9d484527/germany_pharmaceut) has announced the addition of the "Germany Pharmaceuticals and Healthcare Report Q2 2012" report to their offering.

Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and healthcare sector, as well as the impact of generic competition as a result of the patent cliff, BMI expect Germany to remain attractive to innovative drugmakers.

Headline Expenditure Projections

- Pharmaceuticals: EUR39.39bn (US$55.15bn) in 2011 to EUR38.40bn (US$51.46bn) in 2012; -2.5% decline in local currency terms and 6.7% in US dollar terms.

- Halthcare: EUR275.10bn (US$385.15bn) in 2011 to EUR280.97bn (US$376.49bn) in 2012; 2.1% growth in local currency terms and -2.2% in US dollar terms.

- Medical devices: EUR14.97bn (US$22.96bn) in 2011 to EUR15.64bn (US$20.95bn) in 2012; 4.5% growth in local currency terms and no growth in US dollar terms. Forecasts unchanged from Q411.

Key Trends And Developments

- In December 2011, positive news for multinational drugmaker AstraZeneca, the company's Brilique (ticagrelor) for patients with acute coronary syndromes (ACS (News - Alert)) has passed Germany's new cost-benefit assessment. Ticagrelor is the first reversibly binding oral P2Y12 adenosine diphosphate receptor antagonist and the first in a new class of drugs, cyclo-pentyl-triazolo-pyrimidines (CPTPs), which are chemically distinct from thienopyridines such as BMS/Sanofi's Plavix (clopidogrel) and Eli Lilly/Daiichi Sankyo's Effient (prasugrel).

- In January 2012, in negative news for multinational drugmakers Eli Lilly and Boehringer Ingelheim, Trajenta (linagliptin) for patients with type 2 diabetes did not pass the Institute for Quality and Efficiency in Healthcare (IQWiG)'s assessment (a part of the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) cost-benefit assessment).

Companies Mentioned

- Bayer HealthCare

- Boehringer Ingelheim

- Stada Arzneimittel

- Grünenthal

- Merck KGaA

- GlaxoSmithKline (GSK)

- Pfizer

- Novartis

- Sanofi

- Merck & Co

For more information visit http://www.researchandmarkets.com/research/9d484527/germany_pharmaceut

[ Back To SIP Trunking Home's Homepage ]